H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $30 from $22 and keeps a Buy rating on the shares. The company reported strong Q3 results as Zoryve again beat expectations, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics Reports Strong Q3 Earnings Call
- Arcutis Biotherapeutics: Strong Sales and Growth Prospects Justify Buy Rating
- Midday Fly By: OpenAI signs new Microsoft deal, PayPal reports Q3 beat
- Arcutis Biotherapeutics rises 26.5%
- Arcutis Biotherapeutics: Strong Q3 Performance and Strategic Growth Drive Buy Rating